Announcement • Jul 01
Physiomics plc Announces Appointment of Jesse Thissen as Chief Operating Officer, Effective July 1, 2026 Physiomics plc announced the promotion of Jesse Thissen to the position of Chief Operating Officer (COO) with immediate effect, effective July 1, 2026. Jesse has served as Head of Biometrics and has played an instrumental role in strengthening the Company's operational capabilities, technical leadership and project delivery. During his tenure, he has led a number of strategic initiatives designed to improve operational efficiency, expand the Company's service offering and enhance its ability to execute increasingly complex and larger-scale client engagements. In his new role as Chief Operating Officer, Jesse will be responsible for overseeing the Company's day-to-day operations, supporting continued excellence in project delivery while driving operational scalability and supporting the Company's next phase of commercial growth. Announcement • May 28
Physiomics Demonstrates Hantavirus Translational Modelling Capability Physiomics plc highlighted the development of a hantavirus translational modelling framework demonstrating the Company's quantitative pharmacology and mechanistic modelling capabilities within infectious disease applications. The framework illustrates how Physiomics can integrate multiple evidence layers into a coherent translational workflow, linking in vitro antiviral screening, concentration-response potency modelling, pharmacokinetic exposure translation, mechanistic PK/PD viral dynamics, and virtual population simulations. The modelling workflow has been designed to demonstrate how quantitative systems pharmacology approaches may be used to assess whether antiviral activity observed in laboratory systems could plausibly translate into meaningful viral suppression under simulated human exposure conditions. Illustrative workflow components include simulated 384-well phenotypic antiviral screening, EC50 and Emax concentration-response modelling, human PK exposure simulations against potency-linked targets, mechanistic viral-load dynamics modelling across differing antiviral modalities, and virtual population and time-to-clearance simulations. The Company believes the framework demonstrates the breadth and flexibility of Physiomics' modelling capabilities and highlights the potential role of mechanistic translational modelling in supporting infectious disease therapeutic development programmes. The material has been prepared for scientific and illustrative purposes only and does not constitute evidence of clinical efficacy for any specific therapeutic compound, nor has there yet been any commercial application of the hantavirus modelling framework. The Company notes that further experimental, preclinical and clinical data would be required before any conclusions regarding therapeutic efficacy could be drawn. Board Change • Apr 30
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Director Ian Bagnall is the most experienced director on the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. 
